ArticleBMJ (Clinical research ed.)1993
Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?
Article in BMJ (Clinical research ed.), 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.
- Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review.Diabetes care · 2010Pooled it
- Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy.PharmacoEconomics · 1997Trial
- Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group.Diabetologia · 1996Trial
- GERBEHRT: a BERT-based model tailored for German electronic health records - potential in chronic kidney disease prediction.BMC medical informatics and decision making · 2026Article
- Chronic kidney disease in Romania: national adjusted prevalence, risk factors, and temporal trends in high-risk groups.BMC nephrology · 2025Article
- Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?BMC nephrology · 2024Review
- Medical Costs Associated With Diabetes Complications in Medicare Beneficiaries Aged 65 Years or Older With Type 1 Diabetes.Diabetes care · 2023Article
- Histological and biochemical effects of Cinnamomum cassia nanoparticles in kidneys of diabetic Sprague-Dawley rats.Bosnian journal of basic medical sciences · 2019Article
- Management of diabetic renal disease.Annals of translational medicine · 2015Review
- Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy.Journal of human hypertension · 2004Article
- Physical activity alters urinary albumin/ creatinine ratio in type 1 diabetic patient.Journal of sports science & medicine · 2004Article
- Cost-effective strategies in the prevention of diabetic nephropathy.PharmacoEconomics · 2004Review
- A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.Journal of human hypertension · 2002Article
- Costs of diabetes. A methodological analysis of the literature.PharmacoEconomics · 1999Article
- The economic appropriateness of laboratory tests.Journal of the Royal Society of Medicine · 1997Review
- ACE inhibition in diabetic patients. Economic implications.PharmacoEconomics · 1996Article
- Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.BMJ (Clinical research ed.) · 1996Article
- Screening to prevent renal failure in diabetic patients. Study's assumptions are unwarranted.BMJ (Clinical research ed.) · 1996Article
- ACE inhibitors in patients with diabetes mellitus. Clinical and economic considerations.PharmacoEconomics · 1996Review
- Costs of insulin-dependent diabetes mellitus.PharmacoEconomics · 1996Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyse the cost-benefit of screening for and antihypertensive treatment of early renal disease indicated by microalbuminuria in patients with insulin dependent diabetes mellitus.
designPreviously published data were used to estimate transition probabilities for each step from normoalbuminuria until death. The effect of intervention on urinary albumin excretion rate by antihypertensive treatment was arbitrarily set at three different levels. All direct costs (screening, antihypertensive treatment, treatment of end stage renal failure) were included in the cost-benefit analysis by using real discount rates of 2.5% and 6%.
settingComputer simulation. SUBJECTS: Simulated cohort of 8000 patients.
main outcome measuresMortality, incidence of diabetic nephropathy, incidence of end stage renal failure, and costs versus savings.
resultsAssuming treatment effects of 33% and 67% median life expectancy increased by four to 14 years, respectively, and the need for dialysis or transplantation decreased by 21% to 63%. Costs and savings would balance if the annual rate of increase of albuminuria was decreased from 20% to 18% a year.
conclusionsScreening and intervention programmes are likely to have life saving effects and lead to considerable economic savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.